Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ

About

Neurocrine Biosciences, Inc. (Neurocrine) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company’s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.53
Market Cap (Mil.):	$847.50
Shares Outstanding (Mil.):	66.73
Dividend:	--
Yield (%):	--

Financials

	NBIX.OQ	Industry	Sector
P/E (TTM):	--	40.13	30.65
EPS (TTM):	-0.10	--	--
ROI:	-3.59	2.36	18.83
ROE:	-4.27	3.58	19.74

Latest News about NBIX.OQ

» More NBIX.OQ News

Competitors

	Price	Change
Pfizer Inc. (PFE.N)	$29.10	-0.30
GlaxoSmithKline plc (GSK.L)	1,665.00p	-11.00
Eli Lilly & Co. (LLY.N)	$51.37	-0.98
Forest Laboratories, Inc. (FRX.N)	$41.84	+0.27
Sanofi SA (SASY.PA)	€80.79	-0.76
Takeda Pharmaceutical Company Limited (4502.T)	¥4,450	+100.00
Transcept Pharmaceuticals Inc (TSPT.OQ)	$3.05	+0.03
Dainippon Sumitomo Pharma Co., Ltd. (4506.T)	¥1,273	+17.00

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - NEUROCRINE BIOSCIENCES INC (NBIX-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
Wright Investors Service Comprehensive Report for Neurocrine Biosciences Inc Provider: Wright Reports	$472.00 Buy
Market Edge Equity Research Report Provider: Market Edge	$10.00 Buy
Neurocrine Biosciences Provider: S&P Capital IQ – STARS Reports	$115.00 Buy
NEUROCRINE BIOSCIENCES INC (NBIX) 12-months forecast Provider: Pechala's Reports	$15.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.